George Washington and Minnesota universities-founded cell therapy developer Catamaran has raised cash to move two assets toward the clinic.
Catamaran Bio, a US-based cancer treatment developer founded out of University of Minnesota and George Washington University (GWU), launched yesterday with $42m of series A funding co-led by Sofinnova Partners and Lightstone Ventures.
Takeda Ventures, a strategic investment arm of pharmaceutical firm Takeda, also took part in the round, as did SV Health Investors and Astellas Venture Management.
Founded in September 2019, Catamaran Bio is developing cell therapies for a broad range of cancers, including solid tumours.
…
